Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지
DOI QR코드

DOI QR Code

The Route of Leishmania tropica Infection Determines Disease Outcome and Protection against Leishmania major in BALB/c Mice

  • Received : 2012.07.05
  • Accepted : 2012.08.30
  • Published : 2013.03.15
Download PDF
⟨ Previous Next ⟩

Abstract

Leishmania tropica is one of the causative agents of leishmaniasis in humans. Routes of infection have been reported to be an important variable for some species of Leishmania parasites. The role of this variable is not clear for L. tropica infection. The aim of this study was to explore the effects of route of L. tropica infection on the disease outcome and immunologic parameters in BALB/c mice. Two routes were used; subcutaneous in the footpad and intradermal in the ear. Mice were challenged by Leishmani major, after establishment of the L. tropica infection, to evaluate the level of protective immunity. Immune responses were assayed at week 1 and week 4 after challenge. The subcutaneous route in the footpad in comparison to the intradermal route in the ear induced significantly more protective immunity against L. major challenge, including higher delayed-type hypersensitivity responses, more rapid lesion resolution, lower parasite loads, and lower levels of IL-10. Our data showed that the route of infection in BALB/c model of L. tropica infection is an important variable and should be considered in developing an appropriate experimental model for L. tropica infections.

Keywords

References

  1. World Health Organization. Control of the Leishmaniases: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases, WHO Technical Report Series, No. 949. Geneva, Switzerland. 2010.
  2. Mahmoudzadeh-Niknam H, Kiaei SS, Iravani D. Viscerotropic growth pattern of Leishmania tropica in BALB/c mice is suggestive of a murine model for human viscerotropic leishmaniasis. Korean J Parasitol 2007; 45: 247-253. https://doi.org/10.3347/kjp.2007.45.4.247
  3. Lira R, Méndez S, Carrera L, Jaffe C, Neva F, Sacks D. Leishmania tropica: the identification and purification of metacyclic promastigotes and use in establishing mouse and hamster models of cutaneous and visceral disease. Exp Parasitol 1998; 89: 331-342. https://doi.org/10.1006/expr.1998.4283
  4. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2: 845-858. https://doi.org/10.1038/nri933
  5. Mahmoudzadeh-Niknam H, Kiaei SS, Iravani D. Leishmania tropica infection, in comparison to Leishmania major, induces lower delayed type hypersensitivity in BALB/c mice. Korean J Parasitol 2007; 45: 103-109. https://doi.org/10.3347/kjp.2007.45.2.103
  6. Constant SL, Lee KS, Bottomly K. Site of antigen delivery can influence T-cell priming: pulmonary environment promotes preferential Th2-type differentiation. Eur J Immunol 2000; 30: 840-847. https://doi.org/10.1002/1521-4141(200003)30:3<840::AID-IMMU840>3.0.CO;2-L
  7. Mendez S, Belkaid Y, Seder RA, Sacks D. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 2002; 20: 3702-3708. https://doi.org/10.1016/S0264-410X(02)00376-6
  8. Bhowmick S, Mazumdar T, Ali N. Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection. Infect Immun 2009; 77: 1514-1523. https://doi.org/10.1128/IAI.01739-07
  9. Tabbara KS, Peters NC, Afrin F, Mendez S, Bertholet S, Belkaid Y, Sacks DL. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect Immun 2005; 73: 4714-4722. https://doi.org/10.1128/IAI.73.8.4714-4722.2005
  10. Belkaid Y, Kamhawi S, Modi G, Valenzuela J, Noben-Trauth N, Rowton E, Ribeiro J, Sacks DL. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 1998; 188: 1941-1953. https://doi.org/10.1084/jem.188.10.1941
  11. Kaur S, Kaur T, Garg N, Mukherjee S, Raina P, Athokpam V. Effect of dose and route of inoculation on the generation of CD4+ Th1/Th2 type of immune response in murine visceral leishmaniasis. Parasitol Res 2008; 103: 1413-1419. https://doi.org/10.1007/s00436-008-1150-x
  12. Mahmoudzadeh-Niknam H, Abrishami F, Doroudian M, Moradi M, Alimohammadian MH, Parvizi P, Hatam GR, Mohebali M, Khalaj V. The problem of mixing up of Leishmania isolates in the laboratory: suggestion of ITS1 gene sequencing for verification of species. Iran J Parasitol 2011; 6: 41-48.
  13. Mahmoudzadeh-Niknam H, Kiaei SS, Iravani D. Protective immunity against Leishmania major induced by Leishmania tropica infection of BALB/c mice. Exp Parasitol 2011; 127: 448-453. https://doi.org/10.1016/j.exppara.2010.10.008
  14. Mahmoudzadeh-Niknam H. Induction of partial protection against Leishmania major in BALB/c mice by Leishmania tropica. Scand J Lab Anim Sci 2004; 31: 201-207.
  15. Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y, Kündig TM, Gander B, Johansen P. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J Control Release 2010; 147: 342-349. https://doi.org/10.1016/j.jconrel.2010.08.012
  16. Cubas R, Zhang S, Kwon S, Sevick-Muraca EM, Li M, Chen C, Yao Q. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother 2009; 32: 118-128. https://doi.org/10.1097/CJI.0b013e31818f13c4
  17. Sacks DL, Melby PC. Animal models for the analysis of immune responses to leishmaniasis. In Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W eds, Current Protocols in Immunology, Vol 4. New York, USA. John Wiley & Sons. 1998, p 19.2.1-19.2.20.
  18. Combadiere B, Liard C. Transcutaneous and intradermal vaccination. Hum Vaccin 2011; 7: 811-827. https://doi.org/10.4161/hv.7.8.16274
  19. Kautz-Neu K, Noordegraaf M, Dinges S, Bennett CL, John D, Clausen BE, von Stebut E. Langerhans cells are negative regulators of the anti-Leishmania response. J Exp Med 2011; 208: 885-891. https://doi.org/10.1084/jem.20102318
  20. Bennett CL, van Rijn E, Jung S, Inaba K, Steinman RM, Kapsenberg ML, Clausen BE. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 2005; 169: 569-576. https://doi.org/10.1083/jcb.200501071
  21. Kirkpatrick CE, Nolan TJ, Farrell JP. Rate of Leishmania-induced skin-lesion development in rodents depends on the site of inoculation. Parasitology 1987; 94: 451-465. https://doi.org/10.1017/S0031182000055803
  22. Baldwin TM, Elso C, Curtis J, Buckingham L, Handman E. The Site of Leishmania major infection determines disease severity and immune responses. Infect Immun 2003; 71: 6830-6834. https://doi.org/10.1128/IAI.71.12.6830-6834.2003

Cited by

  1. Coinjection with TLR2 Agonist Pam3CSK4 Reduces the Pathology of Leishmanization in Mice vol.9, pp.3, 2013, https://doi.org/10.1371/journal.pntd.0003546
  2. Indigenous microbiota and Leishmaniasis vol.38, pp.1, 2013, https://doi.org/10.1111/pim.12279
  3. Cross‐protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis vol.38, pp.2, 2016, https://doi.org/10.1111/pim.12304
  4. Dermotropic Leishmania donovani in Sri Lanka: visceralizing potential in clinical and preclinical studies vol.145, pp.4, 2013, https://doi.org/10.1017/s003118201700169x
  5. Vaccination with whole-cell killed or recombinant leishmanial protein and toll-like receptor agonists against Leishmania tropica in BALB/c mice vol.13, pp.9, 2018, https://doi.org/10.1371/journal.pone.0204491
  6. The outcome of arginase activity inhibition in BALB/c mice hosting Leishmania tropica vol.42, pp.3, 2013, https://doi.org/10.1111/pim.12691
  7. Visualization of Leishmania tropica Infection in BALB/c Mice by Bioluminescence Imaging vol.24, pp.3, 2020, https://doi.org/10.29252/ibj.24.3.164